Derivation of PRISM score (multivariable Cox regression analysis)
| Variable . | Derivation cohort (Cleveland Clinic) . | ||
|---|---|---|---|
| sHR (95% CI) . | P . | Point(s)∗ . | |
| Prior history of VTE† | 5.06 (1.89-13.5) | .001 | 8 |
| Race (Black vs others) | 1.71 (1.03-2.83) | .037 | 1 |
| IMiD use in induction therapy | 2.17 (1.24-3.80) | .006 | 2 |
| Surgery (within 90 d) | 3.44 (1.96-6.02) | <.001 | 5 |
| Abnormal Metaphase cytogenetics | 2.10 (1.24-3.56) | .006 | 2 |
| Risk stratification | Low-risk: score of 0 | ||
| Intermediate-risk: score of 1-6 | |||
| High-risk: score of ≥7 | |||
| c-statistic: 0.622 (0.570-0.674) | |||
| Variable . | Derivation cohort (Cleveland Clinic) . | ||
|---|---|---|---|
| sHR (95% CI) . | P . | Point(s)∗ . | |
| Prior history of VTE† | 5.06 (1.89-13.5) | .001 | 8 |
| Race (Black vs others) | 1.71 (1.03-2.83) | .037 | 1 |
| IMiD use in induction therapy | 2.17 (1.24-3.80) | .006 | 2 |
| Surgery (within 90 d) | 3.44 (1.96-6.02) | <.001 | 5 |
| Abnormal Metaphase cytogenetics | 2.10 (1.24-3.56) | .006 | 2 |
| Risk stratification | Low-risk: score of 0 | ||
| Intermediate-risk: score of 1-6 | |||
| High-risk: score of ≥7 | |||
| c-statistic: 0.622 (0.570-0.674) | |||
Points were assigned based on HR: 1 was subtracted from each sHR, followed by rounding of “sHR-1” to the nearest 0.5, followed by multiplication by 2 to convert into a whole number.
History of VTE refers to VTE at any time before 6 months from the date of treatment initiation. Patients with VTE within 6 months before treatment initiation were excluded.